The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo

Prostate

Volumn 70, Issue 12, 2010, Pages 1359-1370

  Lin, Edwin ^a   Wang, Qingcai ^a   Swenson, Stephen ^a   Jadvar, Hossein ^a   Groshen, Susan ^a   Ye, Wei ^a   Markland, Francis S ^a   Pinski, Jacek ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiogenesis; Bone metastasis; Contortrostatin; Docetaxel; Integrin; Prostate cancer

Indexed keywords

ALPHAVBETA5 INTEGRIN; CONTORTROSTATIN; DOCETAXEL; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL VIABILITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISINTEGRINS; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 77956371198     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21173     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-3927.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
4. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-276.
5. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N. A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-325. (Pubitemid 43338211)
6. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
7. Chung J, Mercurio AM. Contributions of the α6 integrins to breast carcinoma survival and progression. Mol Cells 2004;17:203-209. (Pubitemid 39137066)
8. Parise LV, Lee JW, Juliano RL. New aspects of integrin signaling in cancer. Sem Cancer Biol 2000;10:407-414. (Pubitemid 32181911)
9. Schwartz MA. Integrins, oncogenes, and anchorage independence. J Cell Biol 1997;139:575-578.
10. Clark EA, Brugge JS. Integrins and signal transduction pathways: The road taken. Science 1995;268:233-239.
11. Haywood-Reid PL, Zipf DR, Springer WR. Quantification of integrin subunits on human prostatic cell lines - Comparison of nontumorigenic and tumorigenic lines. Prostate 1997;31:1-8.
12. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KD, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993;119:637-644. (Pubitemid 23238145)
13. Rabinovitz I, Nagle RB, Cress AE. Integrin α6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 1995;13:481-491.
14. Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, Farach-Carson MC, Otey CA, Zhau HE, Chung LWK. Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 2001;12:99-107. (Pubitemid 32194899)
15. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999;59:1655-1664.
16. Swenson S, Costa F, Ernst W, Fujii G, Markland FS. Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiol Haemost Thromb 2005;34:169-176.
17. Swenson S, Costa F, Minea R, Sherwin RP, Ernst W, Fujii G, Yang D, Markland FS Jr. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 2004;3:499-511.
18. Trikha M, De Clerck YA, Markland FS. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res 1994;54:4993-4998.
19. Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, Tsao-Wei D, Markland FS. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res Treat 2000;61:249-260.
20. Zhou Q, Nakada MT, Brooks PC, Swenson SD, Ritter MR, Argounova S, Arnold C, Markland FS. Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5. Biochem Biophys Res Commun 2000;267:350-355.
21. Trikha M, Rote WE, Manley PJ, Lucchesi BR, Markland FS. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb Res 1994;73:39-52. (Pubitemid 24062503)
22. Ritter MR, Zhou Q, Markland FS Jr. Contortrostatin, a snake venom disintegrin, induces alphavbeta3-mediated tyrosine phosphorylation of CAS and FAK in tumor cells. J Cell Biochem 2000;79:28-37.
23. Matthay MA, Thiery JP, Lafont F, Stampfer F, Boyer B. Transient effect of epidermal growth factor on the motility of an immortalized mammary epithelial cell line. J Cell Sci 1993;106(Pt 3):869-878. (Pubitemid 23346799)
24. Liang CC, Park AY, Guan JL. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2:329-333.
25. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748.
26. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P. Intratumoral microvessel density and p53 protein: Correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 1993;55:739-744. (Pubitemid 23354886)
27. Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN, Piana L. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol 1995;103:443-448.
28. Albelda SM, Oliver PD, Romer LH, Buck CA. EndoCAM: A novel endothelial cell-cell adhesion molecule. J Cell Biol 1990;110:1227-1237. (Pubitemid 20136499)
29. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 1997;151:671-677.
30. Ferrero E, Ferrero ME, Pardi R, Zocchi MR. The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function. FEBS Lett 1995;374:323-326.
31. Schimmenti LA, Yan HC, Madri JA, Albelda SM. Platelet endothelial cell adhesion molecule, PECAM-1, modulates cell migration. J Cell Physiol 1992;153:417-428.
32. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
33. Cheresh DA. Structural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med 1992;12:217-236.
34. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255-1263. (Pubitemid 28128883)
35. Brooks PC, Montgomery AM, Rosenfeld M, Resifeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164.
36. Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, Plow EF. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins. Mol Cell 2000;6:851-860.
37. Zhou Q, Nakada MT, Arnold C, Markland FS. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis 1999;3:259-269. (Pubitemid 129644155)
38. Shono T, Mochizuki Y, Kanetake H, Kanda S. Inhibition of FGF-2-mediated chemotaxis of murine brain capillary endothelial cells by cyclic RGDfV peptide through blocking the redistribution of c-Src into focal adhesions. Exp Cell Res 2001;268:169-178. (Pubitemid 32744648)
39. Rusnati M, Tanghetti E, Dell'Era P, Gualandris A, Presta M. Alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell 1997;8:2449-2461. (Pubitemid 27528213)
40. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 2000;156:1673-1683.
41. Swenson S, Ramu S, Markland FS. Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des 2007;13:2860-2871. (Pubitemid 351545889)
42. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500-1502.
43. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M. Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003;20:413-420. (Pubitemid 37108427)
44. Dedhar S, Saulnier R, Nagle R, Overall CM. Specific alterations in the expression of α3β1 and α6β4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis 1993;11:391-400. (Pubitemid 23285492)
45. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583. (Pubitemid 30323983)
46. Sung V, Stubbs JT, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the αvβ3 and αvβ5 integrins. J Cell Phys 1998;176:482-494.
47. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007;26:6238-6243. (Pubitemid 47414368)
48. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P. Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007;67:5821-5830.